Si è verificato un errore durante il caricamento della pagina.
Il nostro team è stato avvisato ma contattaci tramite il Widget assistenza email se il problema persiste.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 82,4x - 91,1x | 86,8x |
| Selected Fwd EBITDA Multiple | 24,1x - 26,6x | 25,4x |
| Fair Value | ₩8.442 - ₩10.126 | ₩9.284 |
| Upside | 12,3% - 34,7% | 23,5% |
| Benchmarks | Ticker | Full Ticker |
| Theragen Etex Co.,Ltd. | A066700 | KOSDAQ:A066700 |
| JETEMA, Co., Ltd. | A216080 | KOSDAQ:A216080 |
| Aprogen Biologics Inc. | A003060 | KOSE:A003060 |
| CMG Pharmaceutical Co., Ltd. | A058820 | KOSDAQ:A058820 |
| KOREA PHARMA Co., Ltd. | A032300 | KOSDAQ:A032300 |
| Jeil Pharma Holdings Inc | A002620 | KOSE:A002620 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| A066700 | A216080 | A003060 | A058820 | A032300 | A002620 | ||
| KOSDAQ:A066700 | KOSDAQ:A216080 | KOSE:A003060 | KOSDAQ:A058820 | KOSDAQ:A032300 | KOSE:A002620 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | 18.7% | NM- | NM- | -1.5% | 0.1% | -29.3% | |
| 3Y CAGR | NM- | 69.4% | NM- | NM- | 6.3% | 605.5% | |
| Latest Twelve Months | 2.5% | 18.9% | 19.9% | -22.0% | 2.7% | -91.3% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 4.2% | 19.3% | -19.2% | 5.6% | 10.1% | 1.8% | |
| Prior Fiscal Year | 8.0% | 18.7% | -56.4% | 6.0% | 10.4% | 4.2% | |
| Latest Fiscal Year | 7.1% | 19.1% | -58.6% | 4.4% | 10.9% | 0.4% | |
| Latest Twelve Months | 7.1% | 19.1% | -58.6% | 4.4% | 10.9% | 0.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 0.47x | 5.23x | 3.51x | 2.41x | 1.58x | 0.30x | |
| EV / LTM EBITDA | 6.6x | 27.4x | -6.0x | 54.7x | 14.5x | 79.3x | |
| EV / LTM EBIT | 10.0x | 89.9x | -4.0x | 233.9x | 21.1x | -20.7x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -6.0x | 14.5x | 54.7x | ||||
| Historical EV / LTM EBITDA | -166.7x | 24.2x | 79.3x | ||||
| Selected EV / LTM EBITDA | 82.4x | 86.8x | 91.1x | ||||
| (x) LTM EBITDA | 2,918 | 2,918 | 2,918 | ||||
| (=) Implied Enterprise Value | 240,568 | 253,229 | 265,891 | ||||
| (-) Non-shareholder Claims * | (116,020) | (116,020) | (116,020) | ||||
| (=) Equity Value | 124,548 | 137,209 | 149,871 | ||||
| (/) Shares Outstanding | 15.4 | 15.4 | 15.4 | ||||
| Implied Value Range | 8,113.26 | 8,938.06 | 9,762.85 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 8,113.26 | 8,938.06 | 9,762.85 | 7,520.00 | |||
| Upside / (Downside) | 7.9% | 18.9% | 29.8% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A066700 | A216080 | A003060 | A058820 | A032300 | A002620 | |
| Enterprise Value | 116,243 | 359,661 | 236,622 | 238,659 | 128,575 | 231,461 | |
| (+) Cash & Short Term Investments | 24,183 | 24,047 | 38,319 | 76,794 | 37,695 | 75,883 | |
| (+) Investments & Other | 21,904 | 6,605 | 91,994 | 46,463 | 5,836 | 93,756 | |
| (-) Debt | (50,476) | (118,381) | (154,017) | (79,965) | (22,902) | (155,212) | |
| (-) Other Liabilities | (18,398) | 856 | (199) | 0 | 0 | (130,447) | |
| (-) Preferred Stock | 0 | (728) | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 93,456 | 272,060 | 212,718 | 281,951 | 149,204 | 115,440 | |
| (/) Shares Outstanding | 32.0 | 35.8 | 311.0 | 138.9 | 10.9 | 15.4 | |
| Implied Stock Price | 2,920.00 | 7,590.00 | 684.00 | 2,030.00 | 13,680.00 | 7,520.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2,920.00 | 7,590.00 | 684.00 | 2,030.00 | 13,680.00 | 7,520.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |